Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.42 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.42 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.42 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.42 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1283218 | 0.93 | ACHE (0.47) | KDM4ECHEK2ACHEADORA2AADORA1 | |
| SCHEMBL1282878 | 0.91 | ACHE (0.43) | KDM4ECHEK2ACHEADORA2AADORA1 | |
| SCHEMBL1283429 | 0.90 | ACHE (0.46) | KDM4ECHEK2ACHEADORA2AADORA1 | |
| SCHEMBL1283633 | 0.90 | AGER (0.43) | KDM4ECHEK2ACHEADORA2AADORA1 | |
| SCHEMBL1283302 | 0.88 | ADORA2A (0.42) | KDM4ECHEK2ACHEADORA2AADORA1 | |
| SCHEMBL1283598 | 0.87 | CYP11B1 (0.47) | KDM4ECHEK2ACHEADORA2AADORA1 | |
| SCHEMBL1283723 | 0.86 | GALR3 (0.43) | CHEK2ACHEADORA2AADORA1MAP4K4 | |
| SCHEMBL1283068 | 0.85 | ADORA2A (0.40) | KDM4ECHEK2ACHEADORA2AADORA1 | |
| SCHEMBL1615381 | 0.85 | ACHE (0.51) | KDM4ECHEK2ACHEADORA2AADORA1 | |
| SCHEMBL1615374 | 0.83 | CHEK2 (0.46) | KDM4ECHEK2ACHEMAP4K4PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2010-10-07 | — | — | US | disclosed |
| US-7737285-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737285-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7714013-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714013-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7361678-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361678-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-01-25 | — | — | US | disclosed |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | KDM4E 4107/4885CHEK2 3000/4885ACHE 1276/4885 |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | KDM4E 4138/4885CHEK2 2982/4885ACHE 1301/4885 |
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | AGER, S100A4, S100B | KDM4E 4138/4885CHEK2 2982/4885ACHE 1301/4885 |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | KDM4E 4138/4885CHEK2 2982/4885ACHE 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.